US2013011396A1PendingUtilityA1

Treatment protocol

Assignee: WEISENTHAL LARRY MARKPriority: May 22, 2008Filed: Sep 14, 2012Published: Jan 10, 2013

Est. expiryMay 22, 2028(~1.8 yrs left)· nominal 20-yr term from priority

Inventors:Larry M. Weisenthal

G01N 33/52G01N 33/5091A61P 9/00A61K 39/3955G01N 2510/00A61K 45/06

PatentIndex Score

Cited by

References

Claims

Abstract

Combination treatments with an antiangiogenesis agent and non-toxic blood levels of ethanol and/or DMSO are disclosed.

Claims

exact text as granted — not AI-modified

1 . A method to treat conditions characterized by unwanted neovasculature in a subject which method comprises administering to a subject in need of such treatment
 an antiangiogenesis agent   combined with maintaining sub-toxic blood levels of ethanol and/or DMSO.   
     
     
         2 . The method of  claim 1  wherein the antiangiogenesis agent effects endothelial cell death. 
     
     
         3 . The method of  claim 2  wherein the angiogenesis agent is an inhibitor of vascular endothelial growth factor (VEGF). 
     
     
         4 . The method of  claim 1  wherein the antiangiogenesis agent is bevacizumab. 
     
     
         5 . The method of  claim 1  wherein the DMSO is administered intravenously. 
     
     
         6 . The method of  claim 3  wherein the ethanol is administered orally. 
     
     
         7 . The method of  claim 6  wherein the ethanol level is monitored with a breathalyzer.

Join the waitlist — get patent alerts

Track US2013011396A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.